Directorate change
![]()
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the “Group”)
Directorate Change
Former Procter & Gamble Senior Executive to Join SkinBioTherapeutics Board
FY26 results to be announced in November 2026
10 November 2026 – SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health announces the appointment of Gill Whitty-Collins, former Senior Vice President of P&G Beauty at Procter & Gamble, as a Non-Executive Director. She will also be Chair of the Remuneration Committee.
Gill Whitty-Collins spent 26 years with Procter & Gamble where she led global brands including Always, Pantene and Olay, and progressed through the roles of Marketing Director and General Manager to Senior Vice President. Her board experience includes a current Trustee role at 50:50 Parliament and she was a NED at Cellular Goods and Chair of Swiss Netball.
Since leaving Procter & Gamble, she has had a portfolio career, as a keynote speaker, board member, consultant and coach, drawing on her experience in business leadership, brand building and gender equality. Gill is a Fellow of the RSA (The Royal Society for Arts, Manufacturers and Commerce) and Founder of The Brand Execs. She is also the author of Why Men Win at Work and the follow-up, The How to Win at Work Book. She is a graduate of Cambridge University.
Alyson Levett, Chair of SkinBioTherapeutics plc, said:
“We are delighted to welcome Gill to the Board. She has more than two decades of experience of building and managing major consumer brands, and has a clear understanding of how to turn brand strategy into commercial results. Her experience in leadership and organisational culture will also be valuable as we continue to strengthen the business. Gill brings an important additional commercial perspective to the board and we look forward to working with her as we build on the progress made and focus on delivering the groups growth potential.”
The Company intends to report its FY26 results in November 2026 and will be issuing a notice of results in due course.
The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:
|
Full name: |
Gillian Suzanne Whitty-Collins |
|
Age: |
56 |
|
Shareholding in SkinBioTherapeutics: |
None |
|
Current directorships held: |
The Brand Execs International Limited |
|
Directorships held in the previous 5 years: |
Astrid Intelligence PLC |
-Ends-
Images
|
Gill Whitty-Collins |
|
|
For more information please contact:
|
SkinBioTherapeutics plc |
ir@skinbiotix.com
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
+44 (0) 020 7496 3000
|
|
Vigo Consulting |
+44 (0) 20 7390 0230 |
|
|
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life sciences company focused on skin health. The Group’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Company’s strategic approach to skin health is via two routes – tackling skin issues from the ‘outside in’ and the ‘inside out’. The ‘outside in’ approach is represented by topical creams, and from the ‘inside out’, via oral supplement solutions which impact the skin via different axes such as the gut and the brain.
SkinBio’s products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.
The Company listed on AIM in April 2017. For more information, visit: www.SkinBioTherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE